—
C+
C+ The full Closelook — membership. Open the C+ overview

Incyte Corporation (INCY) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Incyte Corporation

INCY in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Incyte develops and sells prescription medicines for blood cancers, certain solid tumours and inflammatory skin conditions, marketed mainly in the United States, Europe, Canada and Japan. Its lead product, Jakafi, treats myelofibrosis, polycythemia vera and a form of graft-versus-host disease, while other approved drugs address leukaemia, lymphoma and rare cancers. The company also runs a pipeline of experimental compounds for blood disorders, skin conditions and solid tumours, partly through collaborations with larger drugmakers such as Novartis and Lilly.
Where it sits in the stack
Incyte carries no seat in our index; it belongs to the healthcare sector of our universe, within biotechnology, where it counts as a commercial-stage drugmaker rather than an early pipeline name.
Who it is priced against
The diary has no peer group set for Incyte; a name the market compares it with is Bristol Myers Squibb, whose Inrebic competes with Jakafi in myelofibrosis.
Why Closelook tracks it
Incyte is an S&P 500 constituent; it does not yet carry a Closelook score, and the diary has not quoted it in any edition.
What the diary watches
Whether newer programmes in skin conditions such as atopic dermatitis and prurigo nodularis, or the ovarian cancer and solid tumour candidates, move from clinical stage toward approval.

Incyte Corporation (INCY) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for INCY, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Canaccord, 2026-08-20

The Street on this name

Analyst actions and the latest print for INCY from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Canaccord — target 152 Target set to $152 (+18.3% to spot) 2026-08-20

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against INCY on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is Incyte Corporation (INCY)?

Incyte Corporation trades as INCY on the US exchange (United States) in the Closelook research universe, as of the registry build of 2026-09-19.

Is INCY in a Closelook index?

Not currently — Incyte Corporation is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does INCY trade against its moving averages?

Uptrend stack intact: Trades +2.5% vs the 50-day and +18.6% vs the 200-day average, 5.5% below the 52-week high and +54.5% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Incyte Corporation do?

Incyte develops and sells prescription medicines for blood cancers, certain solid tumours and inflammatory skin conditions, marketed mainly in the United States, Europe, Canada and Japan. Its lead product, Jakafi, treats myelofibrosis, polycythemia vera and a form of graft-versus-host disease, while other approved drugs address leukaemia, lymphoma and rare cancers. The company also runs a pipeline of experimental compounds for blood disorders, skin conditions and solid tumours, partly through collaborations with larger drugmakers such as Novartis and Lilly. The diary has no peer group set for Incyte; a name the market compares it with is Bristol Myers Squibb, whose Inrebic competes with Jakafi in myelofibrosis.

Where does Incyte Corporation sit in the AI build-out?

Incyte carries no seat in our index; it belongs to the healthcare sector of our universe, within biotechnology, where it counts as a commercial-stage drugmaker rather than an early pipeline name. Incyte is an S&P 500 constituent; it does not yet carry a Closelook score, and the diary has not quoted it in any edition.

What has Wall Street done on Incyte Corporation recently?

The most recent analyst action on Incyte Corporation on the Closelook wire is a price target by Canaccord on 2026-08-20 (target 152). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for INCY, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.